Research in metastatic prostate cancer is abundant and is advancing the field forward with radiopharmaceuticals such as lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 which have the potential to increase treatment options for patients. Here, FOLH1 is linked to metastatic prostate carcinoma.